Cell Culture-Based Production

Therapeutic Fc-Fusion Proteins

Volumn , Issue , 2013, Pages 67-96

  Huang, Yao Ming ^a   Kshirsagar, Rashmi ^a   Woppmann, Barbara ^a   Ryll, Thomas ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84956586666     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527675272.ch03     Document Type: Chapter

References (155)

1. Ashkenazi, A. and Chamow, S.M. (1997) Immunoadhesins as research tools and therapeutic agents. Curr. Opin. Immunol., 9 (2), 195-200.
2. Capon, D.J., Chamow, S.M., Mordenti, J., Marsters, S.A., Gregory, T., Mitsuya, H., Byrn, R.A., Lucas, C., Wurm, F.M., Groopman, J.E., Broder, S., and Smith, D.H. (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature, 337 (6207), 525-531.
3. Chamow, S.M. and Ashkenazi, A. (1996) Immunoadhesins: principles and applications. Trends Biotechnol., 14 (2), 52-60.
4. Beck, A. and Reichert, J.M. (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. mAbs, 3 (5), 415-416.
5. Czajkowsky, D.M., Hu, J., Shao, Z., and Pleass, R.J. (2012) Fc-fusion proteins: new developments and future perspectives. EMBO Mol. Med., 4 (10), 1015-1028.
6. Huang, C. (2009) Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr. Opin. Biotechnol., 20 (6), 692-699.
7. Suzuki, T., Ishii-Watabe, A., Tada, M., Kobayashi, T., Kanayasu-Toyoda, T., Kawanishi, T., and Yamaguchi, T. (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol., 184 (4), 1968-1976.
8. Chamow, S.M., Duliege, A.M., Ammann, A., Kahn, J.O., Allen, J.D., Eichberg, J.W., Byrn, R.A., Capon, D.J., Ward, R.H., and Ashkenazi, A. (1992) CD4 immunoadhesins in anti-HIV therapy: new developments. Int. J. Cancer Suppl., 7, 69-72.
9. Shimamoto, G., Gegg, C., Boone, T., and Queva, C. (2012) Peptibodies: a flexible alternative format to antibodies. mAbs, 4 (5), 586-591.
10. Dumont, J.A., Liu, T., Low, S.C., Zhang, X., Kamphaus, G., Sakorafas, P., Fraley, C., Drager, D., Reidy, T., McCue, J., Franck, H. W.G., Merricks, E.P., Nichols, T.C., Bitonti, A.J., Pierce, G.F., and Jiang, H. (2012) Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood, 119 (13), 3024-3030.
11. Ghetie, V. and Ward, E.S. (2000) Multiple roles for the major histocompatibility complex class Irelated receptor FcRn. Annu. Rev. Immunol., 18, 739-766.
12. Peters, R.T., Low, S.C., Kamphaus, G.D., Dumont, J.A., Amari, J.V., Lu, Q., Zarbis-Papastoitsis, G., Reidy, T.J., Merricks, E.P., Nichols, T.C., and Bitonti, A.J. (2010) Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood, 115 (10), 2057-2064.
13. Roopenian, D.C. and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol., 7 (9), 715-725.
14. Jiang, X.R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., and Schenerman, M. (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug. Discov., 10 (2), 101-111.
15. McCue, J.T., Selvitelli, K., and Walker, J. (2009) Application of a novel affinity adsorbent for the capture and purification of recombinant Factor VIII compounds. J. Chromatogr. A, 1216 (45), 7824-7830.
16. Choi, B.K., Warburton, S., Lin, H., Patel, R., Boldogh, I., Meehl, M., d'Anjou, M., Pon, L., Stadheim, T.A., and Sethuraman, N. (2012) Improvement of N-glycan site occupancy of therapeutic glycoproteins produced in Pichia pastoris. Appl. Microbiol. Biotechnol., 95 (3), 671-682.
17. Liu, L., Gomathinayagam, S., Hamuro, L., Prueksaritanont, T., Wang, W., Stadheim, T.A., and Hamilton, S.R. (2013) The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in glycoengineered Pichia pastoris. Pharm. Res., 30 (3), 803-812.
18. Zha, D. (2013) Glycoengineered Pichiabased expression of monoclonal antibodies. Methods Mol. Biol., 988, 31-43.
19. Andersen, D.C., Bridges, T., Gawlitzek, M., and Hoy, C. (2000) Multiple cell culture factors can affect the glycosylation of Asn-in CHO-produced tissue-type plasminogen activator. Biotechnol. Bioeng., 70 (1), 25-31.
20. Gawlitzek, M., Ryll, T., Lofgren, J., and Sliwkowski, M.B. (2000) Ammonium alters N-glycan structures of recombinant TNFR-IgG: degradative versus biosynthetic mechanisms. Biotechnol. Bioeng., 68 (6), 637-646.
21. Harris, R.J., Kabakoff, B., Macchi, F.D., Shen, F.J., Kwong, M., Andya, J.D., Shire, S.J., Bjork, N., Totpal, K., and Chen, A.B. (2001) Identification of multiple sources of charge heterogeneity in a recombinant antibody. J. Chromatogr. B Biomed. Sci. Appl., 752 (2), 233-245.
22. Luo, J., Zhang, J., Ren, D., Tsai, W.L., Li, F., Amanullah, A., and Hudson, T. (2012) Probing of C-terminal lysine variation in a recombinant monoclonal antibody production using Chinese hamster ovary cells with chemically defined media. Biotechnol. Bioeng., 109 (9), 2306-2315.
23. Quan, C., Alcala, E., Petkovska, I., Matthews, D., Canova-Davis, E., Taticek, R., and Ma, S. (2008) A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. Anal. Biochem., 373 (2), 179-191.
24. Cacciatore, J.J., Chasin, L.A., and Leonard, E.F. (2010) Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the DHFR-based CHO cell selection system. Biotechnol. Adv., 28 (6), 673-681.
25. Puck, T.T., Cieciura, S.J., and Robinson, A. (1958) Genetics of somatic mammalian cells: III. Long-term cultivation of euploid cells from human and animal subjects. J. Exp. Med., 108 (6), 945-956.
26. Baker, K.N., Rendall, M.H., Hills, A.E., Hoare, M., Freedman, R.B., and James, D.C. (2001) Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. Biotechnol. Bioeng., 73 (3), 188-202.
27. Ghaderi, D., Taylor, R.E., Padler-Karavani, V., Diaz, S., and Varki, A. (2010) Implications of the presence of Nglycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotech., 28 (8), 863-867.
28. Kilgore, B.R., Lucka, A.W., Patel, R., Andrien, B.A., Jr., and Dhume, S.T. (2008) Comparability and monitoring immunogenic N-linked oligosaccharides from recombinant monoclonal antibodies from two different cell lines using HPLC with fluorescence detection and mass spectrometry. Methods Mol. Biol., 446, 333-346.
29. Qian, J., Liu, T., Yang, L., Daus, A., Crowley, R., and Zhou, Q. (2007) Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupolequadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal. Biochem., 364 (1), 8-18.
30. Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M., Murphy, B.A., Satinover, S.M., Hosen, J., Mauro, D., Slebos, R.J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D.J., and Platts-Mills, T.A. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N. Engl. J. Med., 358 (11), 1109-1117.
31. Bosques, C.J., Collins, B.E., Meador, J.W., 3rd, Sarvaiya, H., Murphy, J.L., Dellorusso, G., Bulik, D.A., Hsu, I.H., Washburn, N., Sipsey, S.F., Myette, J.R., Raman, R., Shriver, Z., Sasisekharan, R., and Venkataraman, G. (2010) Chinese hamster ovary cells can produce galactose-alpha-1,3-galactose antigens on proteins. Nat. Biotechnol., 28 (11), 1153-1156.
32. Noguchi, A., Mukuria, C.J., Suzuki, E., and Naiki, M. (1995) Immunogenicity of Nglycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J. Biochem., 117 (1), 59-62.
33. Ferrari, J., Gunson, J., Lofgren, J., Krummen, L., and Warner, T.G. (1998) Chinese hamster ovary cells with constitutively expressed sialidase antisense RNA produce recombinant DNase in batch culture with increased sialic acid. Biotechnol. Bioeng., 60 (5), 589-595.
34. Meleady, P., Henry, M., Gammell, P., Doolan, P., Sinacore, M., Melville, M., Francullo, L., Leonard, M., Charlebois, T., and Clynes, M. (2008) Proteomic profiling of CHO cells with enhanced rhBMP-2 productivity following co-expression of PACEsol. Proteomics, 8 (13), 2611-2624.
35. Ryll, T. (inventor) (2003) Mammalian cell culture process for producing glycoproteins. Genentech, Inc., assignee. US Patent No. 6,528,286.
36. Son, Y.D., Jeong, Y.T., Park, S.Y., and Kim, J.H. (2011) Enhanced sialylation of recombinant human erythropoietin in Chinese hamster ovary cells by combinatorial engineering of selected genes. Glycobiology, 21 (8), 1019-1028.
37. Weikert, S., Papac, D., Briggs, J., Cowfer, D., Tom, S., Gawlitzek, M., Lofgren, J., Mehta, S., Chisholm, V., Modi, N., Eppler, S., Carroll, K., Chamow, S., Peers, D., Berman, P., and Krummen, L. (1999) Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat. Biotechnol., 17 (11), 1116-1121.
38. Brinkman-Van der Linden, E.C., Sjoberg, E.R., Juneja, L.R., Crocker, P.R., Varki, N., and Varki, A. (2000) Loss of Nglycolylneuraminic acid in human evolution: implications for sialic acid recognition by siglecs. J. Biol. Chem., 275 (12), 8633-8640.
39. Koike, C., Fung, J.J., Geller, D.A., Kannagi, R., Libert, T., Luppi, P., Nakashima, I., Profozich, J., Rudert, W., Sharma, S.B., Starzl, T.E., and Trucco, M. (2002) Molecular basis of evolutionary loss of the alpha 1,3-galactosyltransferase gene in higher primates. J. Biol. Chem., 277 (12), 10114-10120.
40. Berkner, K.L. (1993) Expression of recombinant vitamin K-dependent proteins in mammalian cells: factors IX and VII. Methods Enzymol., 222, 450-477.
41. Shapiro, A.D., Ragni, M.V., Valentino, L.A., Key, N.S., Josephson, N.C., Powel, J.S., Cheng, G., Thompson, A.R., Goyal, J., Tubridy, K.L., Peters, R.T., Dumont, J.A., Euwart, D., Li, L., Hallen, B., Gozzi, P., Bitonti, A.J., Jiang, H., Luk, A., and Pierce, G.F. (2012) Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/ 2a study in hemophilia B patients. Blood, 119 (3), 666-672.
42. Lee, C.J., Seth, G., Tsukuda, J., and Hamilton, R.W. (2009) A clone screening method using mRNA levels to determine specific productivity and product quality for monoclonal antibodies. Biotechnol. Bioeng., 102 (4), 1107-1118.
43. Markely, L.R. and Wang, D.I. (2012) Highthroughput analysis of intraclonal variability of glycoprotein sialylation. Biotechnol. Prog., 28 (2), 591-594.
44. Markely, L.R.A., Jonnalagadda, K.N., Sinacore, M., Ryll, T., and Prajapati, S. (2012) Improvement in accuracy and specificity of high-throughput sialic acid assay. Anal. Methods, 4 (11), 3565-3569.
45. Primack, J., Flynn, G.C., and Pan, H. (2011) A high-throughput microchip-based glycan screening assay for antibody cell culture samples. Electrophoresis, 32 (10), 1129-1132.
46. Wang, D., Liu, W., Han, B., and Xu, R. (2005) The bioreactor: a powerful tool for large-scale culture of animal cells. Curr. Pharm. Biotechnol., 6 (5), 397-403.
47. Warnock, J.N. and Al-Rubeai, M. (2006) Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol. Appl. Biochem., 45, 1-12.
48. Eibl, R., Kaiser, S., Lombriser, R., and Eibl, D. (2010) Disposable bioreactors: the current state-of-the-art and recommended applications in biotechnology. Appl. Microbiol. Biotechnol., 86 (1), 41-49.
49. Loffelholz, C., Kaiser, S.C., Kraume, M., Eibl, R., and Eibl, D. (2013) Dynamic single-use bioreactors used in modern liter-and m3-scale biotechnological processes: engineering characteristics and scaling up. Adv. Biochem. Eng. Biotechnol. doi: 10.1007/10_2013_187
50. Shukla, A.A. and Gottschalk, U. (2013) Single-use disposable technologies for biopharmaceutical manufacturing. Trends Biotechnol., 31 (3), 147-154.
51. Zhang, X., Stettler, M., De Sanctis, D., Perrone, M., Parolini, N., Discacciati, M., De Jesus, M., Hacker, D., Quarteroni, A., and Wurm, F. (2010) Use of orbital shaken disposable bioreactors for mammalian cell cultures from the milliliter-scale to the 1,000-liter scale. Adv. Biochem. Eng. Biotechnol., 115, 33-53.
52. Smelko, J.P., Wiltberger, K.R., Hickman, E.F., Morris, B.J., Blackburn, T.J., and Ryll, T. (2011) Performance of high intensity fed-batch mammalian cell cultures in disposable bioreactor systems. Biotechnol. Prog., 27 (5), 1358-1364.
53. Kelley, B., Jankowski, M., and Booth, J. (2010) An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia, 16 (5), 717-725.
54. Molowa, D.T. and Mazanet, R. (2003) The state of biopharmaceutical manufacturing. Biotechnol. Annu. Rev., 9, 285-302.
55. Giddings, G., Allison, G., Brooks, D., and Carter, A. (2000) Transgenic plants as factories for biopharmaceuticals. Nat. Biotechnol., 18 (11), 1151-1155.
56. Houdebine, L.-M. (1994) Production of pharmaceutical proteins from transgenic animals. J. Biotechnol., 34 (3), 269-287.
57. Kusnadi, A.R., Nikolov, Z.L., and Howard, J.A. (1997) Production of recombinant proteins in transgenic plants: practical considerations. Biotechnol. Bioeng., 56 (5), 473-484.
58. Kelley, B. (2009) Industrialization of mAb production technology: the bioprocessing industry at a crossroads. mAbs, 1 (5), 443-452.
59. Gagnon, M., Hiller, G., Luan, Y.T., Kittredge, A., DeFelice, J., and Drapeau, D. (2011) High-end pH-controlled delivery of glucose effectively suppresses lactate accumulation in CHO fed-batch cultures. Biotechnol. Bioeng., 108 (6), 1328-1337.
60. Huang, Y.M., Hu, W.W., Rustandi, E., Chang, K., Yusuf-Makagiansar, H., and Ryll, T. (2010) Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol. Prog., 26 (5), 1400-1410.
61. Lu, F., Toh, P.C., Burnett, I., Li, F., Hudson, T., Amanullah, A., and Li, J. (2013) Automated dynamic fed-batch process and media optimization for high productivity cell culture process development. Biotechnol. Bioeng., 110 (1), 191-205.
62. Yu, M., Hu, Z., Pacis, E., Vijayasankaran, N., Shen, A., and Li, F. (2011) Understanding the intracellular effect of enhanced nutrient feeding toward high titer antibody production process. Biotechnol. Bioeng., 108 (5), 1078-1088.
63. Wurm, F.M. (2004) Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol., 22 (11), 1393-1398.
64. Horvath, B., Tsang, V.L., Lin, W., Dai, X., Kunas, K., and Frank, G. (2013) A generic growth test method for improving quality control of disposables in industrial cell culture. Biopharm. Int., 26 (6), 34-41.
65. Konstantinov, K., Goudar, C., Ng, M., Meneses, R., Thrift, J., Chuppa, S., Matanguihan, C., Michaels, J., and Naveh, D. (2006) The "push-to-low" approach for optimization of high-density perfusion cultures of animal cells. Adv. Biochem. Eng. Biotechnol., 101, 75-98.
66. Lullau, E., Kanttinen, A., Hassel, J., Berg, M., Haag-Alvarsson, A., Cederbrant, K., Greenberg, B., Fenge, C., and Schweikart, F. (2003) Comparison of batch and perfusion culture in combination with pilot-scale expanded bed purification for the production of soluble recombinant beta-secretase. Biotechnol. Prog., 19 (1), 37-44.
67. Pollock, J., Ho, S.V., and Farid, S.S. (2013) Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty. Biotechnol. Bioeng., 110 (1), 206-219.
68. Ryll, T., Dutina, G., Reyes, A., Gunson, J., Krummen, L., and Etcheverry, T. (2000) Performance of small-scale CHO perfusion cultures using an acoustic cell filtration device for cell retention: characterization of separation ef ficiency and impact of perfusion on product quality. Biotechnol. Bioeng., 69 (4), 440-449.
69. Warikoo, V., Godawat, R., Brower, K., Jain, S., Cummings, D., Simons, E., Johnson, T., Walther, J., Yu, M., Wright, B., McLarty, J., Karey, K.P., Hwang, C., Zhou, W., Riske, F., and Konstantinov, K. (2012) Integrated continuous production of recombinant therapeutic proteins. Biotechnol. Bioeng., 109 (12), 3018-3029.
70. Crucell (2013) http://www.crucell.com/ Technology_-_Cell_Technology_-_Applications_-_Proteins (accessed June 21, 2013).
71. Varley, J. and Birch, J. (1999) Reactor design for large scale suspension animal cell culture. Cytotechnology, 29 (3), 177-205.
72. Nienow, A.W. and Flickinger, M.C. (2009) Impeller selection for animal cell culture, in Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology, John Wiley & Sons, Inc., Hoboken, NJ. doi: 10.1002/ 9780470054581. eib636
73. Yang, J.D., Lu, C., Stasny, B., Henley, J., Guinto, W., Gonzalez, C., Gleason, J., Fung, M., Collopy, B., Benjamino, M., Gangi, J., Hanson, M., and Ille, E. (2007) Fed-batch bioreactor process scale-up from 3-L to 2,500-L scale for monoclonal antibody production from cell culture. Biotechnol. Bioeng., 98 (1), 141-154.
74. Godoy-Silva, R., Berdugo, C., Chalmers, J. J., and Flickinger, M.C. (2009) Aeration, mixing, and hydrodynamics, animal cell bioreactors, in Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology, John Wiley & Sons, Inc., Hoboken, NJ. doi: 10.1002/ 9780470054581. eib010
75. Godoy-Silva, R., Chalmers, J.J., Casnocha, S.A., Bass, L.A., and Ma, N. (2009) Physiological responses of CHO cells to repetitive hydrodynamic stress. Biotechnol. Bioeng., 103 (6), 1103-1117.
76. Hu, W., Berdugo, C., and Chalmers, J.J. (2011) The potential of hydrodynamic damage to animal cells of industrial relevance: current understanding. Cytotechnology, 63 (5), 445-460.
77. Hu, W., Rathman, J.J., and Chalmers, J.J. (2008) An investigation of small-molecule surfactants to potentially replace pluronic F-68 for reducing bubble-associated cell damage. Biotechnol. Bioeng., 101 (1), 119-127.
78. Kilburn, D.G. and Webb, F.C. (2000) The cultivation of animal cells at controlled dissolved oxygen partial pressure. Biotechnol. Bioeng., 67 (6), 657-670.
79. Ma, N., Chalmers, J.J., Aunins, J.G., Zhou, W., and Xie, L. (2004) Quantitative studies of cell-bubble interactions and cell damage at different pluronic F-68 and cell concentrations. Biotechnol. Prog., 20 (4), 1183-1191.
80. Zhu, Y., Cuenca, J.V., Zhou, W., and Varma, A. (2008) NS0 cell damage by high gas velocity sparging in protein-free and cholesterol-free cultures. Biotechnol. Bioeng., 101 (4), 751-760.
81. Yang, L., Hu, W., Wiltberger, K., Ryll, T., and Li, F. (2013) Effects of bubble-liquid two-phase turbulent hydrodynamics on cell damage in sparged bioreactor. Biotechnol. Prog. doi: 10.1002/btpr.1790.
82. Kirdar, A.O., Chen, G., Weidner, J., and Rathore, A.S. (2010) Application of nearinfrared (NIR) spectroscopy for screening of raw materials used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol. Prog., 26 (2), 527-531.
83. Li, G. and Wen, Z.-q. (2013) Screening soy hydrolysates for the production of a recombinant therapeutic protein in commercial cell line by combined approach of near-infrared spectroscopy and chemometrics. Appl. Microbiol. Biotechnol., 97 (6), 2653-2660.
84. Luo, Y. and Chen, G. (2007) Combined approach of NMR and chemometrics for screening peptones used in the cell culture medium for the production of a recombinant therapeutic protein. Biotechnol. Bioeng., 97 (6), 1654-1659.
85. Jayme, D.W. (1991) Nutrient optimization for high density biological production applications. Cytotechnology, 5 (1), 15-30.
86. Schlaeger, E.J. (1996) The protein hydrolysate, Primatone RL, is a costeffective multiple growth promoter of mammalian cell culture in serumcontaining and serum-free media and displays anti-apoptosis properties. J. Immunol. Methods, 194 (2), 191-199.
87. Garnick, R.L. (1998) Raw materials as a source of contamination in large-scale cell culture, in Safety of Biological Products Prepared from Mammalian Cell Culture (eds F. Brown, E. Griffiths, F. Horaud, and J.C. Petriccianipp), vol. 93, S Karger Pub, pp. 21-29.
88. Heidemann, R., Zhang, C., Qi, H., Larrick Rule, J., Rozales, C., Park, S., Chuppa, S., Ray, M., Michaels, J., Konstantinov, K., and Naveh, D. (2000) The use of peptones as medium additives for the production of a recombinant therapeutic protein in high density perfusion cultures of mammalian cells. Cytotechnology, 32 (2), 157-167.
89. Mosser, M., Chevalot, I., Olmos, E., Blanchard, F., Kapel, R., Oriol, E., Marc, I., and Marc, A. (2012) Combination of yeast hydrolysates to improve CHO cell growth and IgG production. Cytotechnology. doi: 10.1007/s10616-012-9519-1
90. Fiske, T. (2010) Biogen Idec, Wyeth Biopharma Create Value from Data, PharmaManufacturing. com. (011), http:// www.pharmamanufacturing.com/articles/ 2010/011.html.
91. Opel, C.F., Li, J., and Amanullah, A. (2010) Quantitative modeling of viable cell density, cell size, intracellular conductivity, and membrane capacitance in batch and fed-batch CHO processes using dielectric spectroscopy. Biotechnol. Prog., 26 (4), 1187-1199.
92. Abu-Absi, N.R., Kenty, B.M., Cuellar, M.E., Borys, M.C., Sakhamuri, S., Strachan, D.J., Hausladen, M.C., and Li, Z.J. (2011) Real time monitoring of multiple parameters in mammalian cell culture bioreactors using an in-line Raman spectroscopy probe. Biotechnol. Bioeng., 108 (5), 1215-1221.
93. Bradley, S.A., Ouyang, A., Purdie, J., Smitka, T.A., Wang, T., and Kaerner, A. (2010) Fermentanomics: monitoring mammalian cell cultures with NMR spectroscopy. J. Am. Chem. Soc., 132 (28), 9531-9533.
94. Jose, G.E., Folque, F., Menezes, J.C., Werz, S., Strauss, U., and Hakemeyer, C. (2011) Predicting Mab product yields from cultivation media components, using nearinfrared and 2D-fluorescence spectroscopies. Biotechnol. Prog., 27 (5), 1339-1346.
95. Li, B., Ryan, P.W., Ray, B.H., Leister, K.J., Sirimuthu, N.M.S., and Ryder, A.G. (2010) Rapid characterization and quality control of complex cell culture media solutions using Raman spectroscopy and chemometrics. Biotechnol. Bioeng., 107 (2), 290-301.
96. Moretto, J., Smelko, J.P., Cuellar, M., Berry, B., Doane, A., Ryll, T., and Wiltberger, K. (2011) Process Raman spectroscopy for in-line CHO cell culture monitoring. Am. Pharm. Rev., 14, 18-25.
97. Reichert, J.M. (2009) Global antibody development trends. mAbs, 1 (1), 86-87.
98. Scolnik, P.A. (2009) mAbs: a business perspective. mAbs, 1 (2), 179-184.
99. Browning, J., Miatkowski, K., and Meier, W. (inventor(s) (2009) Active lymphotoxin-b receptor immunoglobulin chimeric protein compositions. Biogen Idec MA, Inc., assignee. US Patent No. 8,283,138 B2.
100. Etcheverry, T. and Ryll, T. (inventor(s) (1998) Mammalian cell culture process. Genentech, Inc., assignee. 1. US Patent No. 5,705,364.
101. Fung, V.P. (inventor(s) (2007) Method for producing recombinant proteins. Immunex Corporation, assignee. US Patent No. 7,294,481 B1.
102. Jones, A.J.S., Papac, D.I., Chin, E.H., Keck, R., Baughman, S.A., Lin, Y.S., Kneer, J., and Battersby, J.E. (2007) Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology, 17 (5), 529-540.
103. Keck, R., Nayak, N., Lerner, L., Raju, S., Ma, S., Schreitmueller, T., Chamow, S., Moorhouse, K., Kotts, C., and Jones, A. (2008) Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content. Biologicals, 36 (1), 49-60.
104. Kery, V., Krepinsky, J.F., Warren, C.D., Capek, P., and Stahl, P.D. (1992) Ligand recognition by purified human mannose receptor. Arch. Biochem. Biophys., 298 (1), 49-55.
105. Ashwell, G. and Harford, J. (1982) Carbohydrate-specific receptors of the liver. Annu. Rev. Biochem., 51, 531-554.
106. Stockert, R.J. (1995) The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev., 75 (3), 591-609.
107. Flesher, A.R., Marzowski, J., Wang, W.C., and Raff, H.V. (1995) Fluorophore-labeled carbohydrate analysis of immunoglobulin fusion proteins: correlation of oligosaccharide content with in vivo clearance profile. Biotechnol. Bioeng., 47 (3), 405-405.
108. Meier, W., Gill, A., Rogge, M., Dabora, R., Majeau, G.R., Oleson, F.B., Jones, W.E., Frazier, D., Miatkowski, K., and Hochman, P.S. (1995) Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther. Immunol., 2 (3), 159-171.
109. Thotakura, N.R., Desai, R.K., Bates, L.G., Cole, E.S., Pratt, B.M., and Weintraub, B. D. (1991) Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology, 128 (1), 341-348.
110. Jenkins, N. and Hovey, A. (1993) Temperature control of growth and productivity in mutant Chinese hamster ovary cells synthesizing a recombinant protein. Biotechnol. Bioeng., 42 (9), 1029-1036.
111. Weidemann, R., Ludwig, A., and Kretzmer, G. (1994) Low temperature cultivation: a step towards process optimisation. Cytotechnology, 15 (1-3), 111-116.
112. Moore, A., Mercer, J., Dutina, G., Donahue, C.J., Bauer, K.D., Mather, J.P., Etcheverry, T., and Ryll, T. (1997) Effects of temperature shift on cell cycle, apoptosis and nucleotide pools in CHO cell batch cultures. Cytotechnology, 23 (1-3), 47-54.
113. Ozturk, S.S. and Palsson, B.O. (1991) Effect of medium osmolarity on hybridoma growth, metabolism, and antibody production. Biotechnol. Bioeng., 37 (10), 989-993.
114. Lee, M.S. and Lee, G.M. (2000) Hyperosmotic pressure enhances immunoglobulin transcription rates and secretion rates of KR12H-2 transfectoma. Biotechnol. Bioeng., 68 (3), 260-268.
115. Dorner, A.J., Wasley, L.C., and Kaufman, R.J. (1989) Increased synthesis of secreted proteins induces expression of glucoseregulated proteins in butyrate-treated Chinese hamster ovary cells. J. Biol. Chem., 264 (34), 20602-20607.
116. Gorman, C.M., Howard, B.H., and Reeves, R. (1983) Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res., 11 (21), 7631-7648.
117. Palermo, D.P., DeGraaf, M.E., Marotti, K. R., Rehberg, E., and Post, L.E. (1991) Production of analytical quantities of recombinant proteins in Chinese hamster ovary cells using sodium butyrate to elevate gene expression. J. Biotechnol., 19 (1), 35-47.
118. Bode, K.A., Schroder, K., Hume, D.A., Ravasi, T., Heeg, K., Sweet, M.J., and Dalpke, A.H. (2007) Histone deacetylase inhibitors decrease Toll-like receptormediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology, 122 (4), 596-606.
119. Hendrick, V., Winnepenninckx, P., Abdelkafi, C., Vandeputte, O., Cherlet, M., Marique, T., Renemann, G., Loa, A., Kretzmer, G., and Werenne, J. (2001) Increased productivity of recombinant tissular plasminogen activator (t-PA) by butyrate and shift of temperature: a cell cycle phases analysis. Cytotechnology, 36 (1-3), 71-83.
120. Backliwal, G., Hildinger, M., Kuettel, I., Delegrange, F., Hacker, D.L., and Wurm, F.M. (2008) Valproic acid: a viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. Biotechnol. Bioeng., 101 (1), 182-189.
121. Kuwae, S., Ohda, T., Tamashima, H., Miki, H., and Kobayashi, K. (2005) Development of a fed-batch culture process for enhanced production of recombinant human antithrombin by Chinese hamster ovary cells. J. Biosci. Bioeng., 100 (5), 502-510.
122. Li, J., Wong, C.L., Vijayasankaran, N., Hudson, T., and Amanullah, A. (2012) Feeding lactate for CHO cell culture processes: impact on culture metabolism and performance. Biotechnol. Bioeng., 109 (5), 1173-1186.
123. Trummer, E., Fauland, K., Seidinger, S., Schriebl, K., Lattenmayer, C., Kunert, R., Vorauer-Uhl, K., Weik, R., Borth, N., Katinger, H., and Muller, D. (2006) Process parameter shifting: Part I. Effect of DOT, pH, and temperature on the performance of Epo-Fc expressing CHO cells cultivated in controlled batch bioreactors. Biotechnol. Bioeng., 94 (6), 1033-1044.
124. Link, T., Backstrom, M., Graham, R., Essers, R., Zorner, K., Gatgens, J., Burchell, J., Taylor-Papadimitriou, J., Hansson, G.C., and Noll, T. (2004) Bioprocess development for the production of a recombinant MUC1 fusion protein expressed by CHO-K1 cells in protein-free medium. J. Biotechnol., 110 (1), 51-62.
125. Kunkel, J.P., Jan, D.C., Jamieson, J.C., and Butler, M. (1998) Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. J. Biotechnol., 62 (1), 55-71.
126. Lin, A.A., Kimura, R., andMiller, W.M. (1993) Production of tPA in recombinant CHO cells under oxygen-limited conditions. Biotechnol. Bioeng., 42 (3), 339-350.
127. Restelli, V., Wang, M.D., Huzel, N., Ethier, M., Perreault, H., and Butler, M. (2006) The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cells. Biotechnol. Bioeng., 94 (3), 481-494.
128. 2 removal in large-scale fed-batch cultures. Biotechnol. Prog., 19 (1), 45-51.
129. 2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: a case study. Biotechnol. Prog., 21 (1), 70-77.
130. 2 and osmolality: intracellular pH, cell size, apoptosis, and metabolism. Biotechnol. Bioeng., 77 (4), 369-380.
131. 2 or pH. Biotechnol. Bioeng., 65 (2), 182-191.
132. Khetan, A., Huang, Y.-m., Dolnikova, J., Pederson, N.E., Wen, D., Yusuf-Makagiansar, H., Chen, P., and Ryll, T. (2010) Control of misincorporation of serine for asparagine during antibody production using CHO cells. Biotechnol. Bioeng., 107 (1), 116-123.
133. Kshirsagar, R., McElearney, K., Gilbert, A., Sinacore, M., and Ryll, T. (2012) Controlling trisulfide modification in recombinant monoclonal antibody produced in fed-batch cell culture. Biotechnol. Bioeng., 109 (10), 2523-2532.
134. Yuk, I.H., Zhang, B.Y., Yang, Y., Dutina, G., Leach, K.D., Vijayasankaran, N., Shen, A.Y., Andersen, D.C., Snedecor, B.R., and Joly, J.C. (2011) Controlling glycation of recombinant antibody in fed-batch cell cultures. Biotechnol. Bioeng., 108 (11), 2600-2610.
135. Borys, M.C., Dalal, N.G., Abu-Absi, N.R., Khattak, S.F., Jing, Y., Xing, Z., and Li, Z.J. (2010) Effects of culture conditions on Nglycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells. Biotechnol. Bioeng., 105 (6), 1048-1057.
136. 2. Biotechnol. Prog., 13 (3), 311-317.
137. Blumen, T.K., Grampp, G.E., and Hettwer, D.J. (inventor(s) (1995) Methods for controlling sialic acid derivatives in recombinant glycoproteins. Amgen, Inc., assignee. US Patent No. 5,459,031.
138. Gramer, M.J., Goochee, C.F., Chock, V.Y., Brousseau, D.T., and Sliwkowski, M.B. (1995) Removal of sialic acid from a glycoprotein in CHO cell culture supernatant by action of an extracellular CHO cell sialidase. Biotechnology (NY), 13 (7), 692-698.
139. Ryll, T. (inventor(s) (2004) Galactosylation of recombinant glycoproteins. Genentech (pending), assignee. US Patent No. 2003/ 0211573 A1.
140. von Horsten, H.H., Ogorek, C., Blanchard, V., Demmler, C., Giese, C., Winkler, K., Kaup, M., Berger, M., Jordan, I., and Sandig, V. (2010) Production of nonfucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase. Glycobiology, 20 (12), 1607-1618.
141. Hills, A.E., Patel, A., Boyd, P., and James, D.C. (2001) Metabolic control of recombinant monoclonal antibody Nglycosylation in GS-NS0 cells. Biotechnol. Bioeng., 75 (2), 239-251.
142. Rodriguez, J., Spearman, M., Huzel, N., and Butler, M. (2005) Enhanced production of monomeric interferon-b by CHO cells through the control of culture conditions. Biotechnol. Prog., 21 (1), 22-30.
143. Jing, Y., Qian, Y., and Li, Z.J. (2010) Sialylation enhancement of CTLA4-Ig fusion protein in Chinese hamster ovary cells by dexamethasone. Biotechnol. Bioeng., 107 (3), 488-496.
144. Rouiller, Y., Perilleux, A., Marsaut, M., Stettler, M., Vesin, M.N., and Broly, H. (2012) Effect of hydrocortisone on the production and glycosylation of an Fcfusion protein in CHO cell cultures. Biotechnol. Prog., 28 (3), 803-813.
145. Gramer, M.J. and Goochee, C.F. (1993) Glycosidase activities in Chinese hamster ovary cell lysate and cell culture supernatant. Biotechnol. Prog., 9 (4), 366-373.
146. Gramer, M.J. and Goochee, C.F. (1994) Glycosidase activities of the 293 and NSO cell lines, and of an antibody-producing hybridoma cell line. Biotechnol. Bioeng., 43 (5), 423-428.
147. Muthing, J., Kemminer, S.E., Conradt, H. S., Sagi, D., Nimtz, M., Karst, U., and Peter-Katalinic, J. (2003) Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti-melanoma mouse IgG3 monoclonal antibody R24. Biotechnol. Bioeng., 83 (3), 321-334.
148. Yoon, S.K., Choi, S.L., Song, J.Y., and Lee, G.M. (2005) Effect of culture pH on erythropoietin production by Chinese hamster ovary cells grown in suspension at 32.5 and 37.0 degrees C. Biotechnol. Bioeng., 89 (3), 345-356.
149. Rivinoja, A., Hassinen, A., Kokkonen, N., Kauppila, A., and Kellokumpu, S. (2009) Elevated Golgi pH impairs terminal Nglycosylation by inducing mislocalization of Golgi glycosyltransferases. J. Cell Physiol., 220 (1), 144-154.
150. Hodoniczky, J., Zheng, Y.Z., and James, D.C. (2005) Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog., 21 (6), 1644-1652.
151. Raju, T.S., Briggs, J.B., Chamow, S.M., Winkler, M.E., and Jones, A.J. (2001) Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. Biochemistry, 40 (30), 8868-8876.
152. Gatumu, M.K., Skarstein, K., Papandile, A., Browning, J.L., Fava, R.A., and Bolstad, A.I. (2009) Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res. Ther., 11 (1), R24.
153. Chiang, G.G. and Sisk, W.P. (2005) Bcl-x(L) mediates increased production of humanized monoclonal antibodies in chinese hamster ovary cells. Biotechnol. Bioeng., 91 (7), 779-792.
154. Swiech, K., Picanco-Castro, V., and Covas, D.T. (2012) Human cells: new platform for recombinant therapeutic protein production. Protein Expr. Purif., 84 (1), 147-153.
155. Harrison, S., Adamson, S., Bonam, D., Brodeur, S., Charlebois, T., Clancy, B., Costigan, R., Drapeau, D., Hamilton, M., Hanley, K., Kelley, B., Knight, A., Leonard, M., McCarthy, M., Oakes, P., Sterl, K., Switzer, M., Walsh, R., and Foster, W. (1998) The manufacturing process for recombinant factor IX. Semin. Hematol., 35 (2 Suppl. 2), 4-10.